Khorana评分预测癌症患者静脉血栓栓塞:个体患者数据Meta分析
本个体患者数据Meta分析纳入7项随机对照试验中3293例有Khorana评分的实体瘤患者,评估Khorana评分对6个月VTE风险的预测效能及低分子肝素在高危患者中的疗效与安全性。结果显示该评分在肺癌患者中无法分层VTE风险,但在其他癌症类型中高危评分与VTE风险增加相关,且高危患者接受低分子肝素可显著降低VTE风险而不增加大出血。
要点
- Khorana评分在肺癌患者中无法分层6个月VTE风险。
- 其他癌症类型中,高危评分者VTE风险较低中危者增加约三倍。
- 高危Khorana评分患者使用低分子肝素可降低VTE风险且不增加大出血。
核心结论
- Khorana评分无法在肺癌患者中分层VTE风险。
- 其他癌症类型中,高危评分与低中危评分相比VTE风险增加约三倍。
- 高危Khorana评分患者接受血栓预防有效且安全。
研究设计与样本
- 个体患者数据Meta分析,评估实体瘤患者使用(超)低分子肝素,数据来自7项随机对照试验。
- 分析对照组中有Khorana评分的3293例患者,包括肺癌1913例(58%)、结直肠癌452例(14%)、胰腺癌264例(8%)、胃癌201例(6%)、卵巢癌184例(56%)、乳腺癌164例(5%)、脑癌84例(3%)、膀胱癌31例(1%)。
主要发现
- 高危Khorana评分患者6个月VTE发生率为9.8%,低中危患者为6.4%(OR 1.6;95% CI 1.1-2.2)。
- 二分法Khorana评分在肺癌患者中OR 1.1(95% CI 0.72-1.7),在其他癌症类型中OR 3.2(95% CI 1.8-5.6;Pinteraction = .002)。
- 高危患者中,低分子肝素较对照组降低VTE风险64%(OR 0.36;95% CI 0.22-0.58),不增加大出血风险(OR 1.1;95% CI 0.59-2.1)。
关键数值与推荐
- 高危Khorana评分患者6个月VTE发生率为9.8%,低中危为6.4%。
- 高危患者低分子肝素降低VTE风险OR 0.36(95% CI 0.22-0.58),大出血OR 1.1(95% CI 0.59-2.1)。
临床怎么用
- 对非肺癌的实体瘤门诊化疗患者,可用Khorana评分识别高危者并以低分子肝素进行初级血栓预防。
- 肺癌患者不宜仅依据Khorana评分分层VTE风险,需考虑其他评估手段。
局限性
- 分析仅纳入对照组中有Khorana评分的患者,可能存在选择偏倚。
- 各癌症类型样本量不均,部分癌种例数较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Oncology guidelines suggest using the Khorana score to select ambulatory cancer patients receiving chemotherapy for primary venous thromboembolism (VTE) prevention, but its performance in different cancers remains uncertain. OBJECTIVE: To examine the performance of the Khorana score in assessing 6-month VTE risk, and the efficacy and safety of low-molecular-weight heparin (LMWH) among high-risk Khorana score patients. METHODS: This individual patient data meta-analysis evaluated (ultra)-LMWH in patients with solid cancer using data from seven randomized controlled trials. RESULTS: A total of 3293 patients from the control groups with an available Khorana score had lung (n = 1913; 58%), colorectal (n = 452; 14%), pancreatic (n = 264; 8%), gastric (n = 201; 6%), ovarian (n = 184; 56%), breast (n = 164; 5%), brain (n = 84; 3%), or bladder cancer (n = 31; 1%). The 6-month VTE incidence was 9.8% among high-risk Khorana score patients and 6.4% among low-to-intermediate-risk patients (odds ratio [OR], 1.6; 95% confidence interval [CI], 1.1-2.2). The dichotomous Khorana score performed differently in lung cancer patients (OR 1.1; 95% CI, 0.72-1.7) than in the group with other cancer types (OR 3.2; 95% CI, 1.8-5.6; Pinteraction = .002). Among high-risk patients, LMWH decreased the risk of VTE by 64% compared with controls (OR 0.36; 95% CI, 0.22-0.58), without increasing the risk of major bleeding (OR 1.1; 95% CI, 0.59-2.1). CONCLUSION: The Khorana score was unable to stratify patients with lung cancer based on their VTE risk. Among those with other cancer types, a high-risk score was associated with a three-fold increased risk of VTE compared with a low-to-intermediate risk score. Thromboprophylaxis was effective and safe in patients with a high-risk Khorana score.
引用
- van Es N, Ventresca M, Di Nisio M, et al. The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. J Thromb Haemost. 2020. PMID: 32336010. doi:10.1111/jth.14824
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。